ORGANIZING COMMITTEE
|
Brendan Larder, Chair
RDI, UK
|
Charles Boucher, Co-Chair
Erasmus University, Erasmus Medical Center, Rotterdam,
Academic Hospital, Utrecht, the Netherlands
|
John Mellors
University of Pittsburgh, USA |
Douglas Richman
VA San Diego Healthcare System and
University of California San Diego, USA |
|
|
|
SCIENTIFIC COMMITTEE
|
|
Barry Bernstein
Abbott Laboratories
|
Daniel Kuritzkes
Brigham and Women's Hospital |
François Clavel
Inserm U552
|
Susan Little
University of California, San Diego |
Bonaventura Clotet
Fundacio IRSI Caixa
|
Doug Mayers
Idenix Pharmaceuticals |
John Coffin
National Cancer Institute-Frederick
|
Michael Miller
Gilead Sciences |
Abel De La Rosa
Pharmasset
|
Carlo Perno
Universita Di Tor Vergata |
Steven Deeks
University of California, San Francisco
|
Christos Petropoulos
Monogram Biosciences |
Matthias Götte
McGill University
|
Deenan Pillay
University College London |
Robert Grant
Gladstone/UCSF
|
Jonathan Schapiro
National Hemophilia Center - Israel |
Huldrych Günthard
University Hospital Zurich
|
Celia Schiffer
University of Massachusetts Medical School
|
David Hall
Boehringer Ingelheim Pharmaceuticals
|
Raymond Schinazi
Emory University/VA Medical Center |
George Hanna
Bristol-Myers Squibb
|
Lieven Stuyver
Tibotec-Virco
|
Richard Harrigan
BC Centre for Excellence in HIV/AIDS
|
Mark Wainberg
McGill University AIDS Centre |
Daria Hazuda
Merck Research Labs
|
Mike Westby
Pfizer Global R&D |
Walid Heneine
Centers for Disease Control and Prevention
|
Jinzi Wu
GlaxoSmithKline |
Kurt Hertogs
Tibotec bvba
|
Andrew Zolopa
Stanford University |
Rolf Kaiser
University of Cologne |
|
